Relationship Between Patient Reports of Urinary Incontinence Symptoms and Quality of Life Measures

Robinson, Deirdre; Pearce, Kevin; Preisser, John S.; Dugan, Elizabeth; Suggs, Patricia K.; Cohen, Stuart J.

doi:10.1016/s0029-7844(97)00627-3

Cited by 82 publications

(54 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The QoL of women with UI is a¡ected by a number of factors. UI type has been shown to di¡erentially a¡ect QoL, and urge UI has been found to have a greater impact on QoL than stress UI Hunskaar and Vinsnes, 1991;Grimby Robinson et al, 1998]. Many other di¡erent factors (e.g., menopause, ageing, obesity, previous gynecologic operations, higher parity, vaginal delivery, jobs involving heavy lifting, and uterovaginal prolapse) have also been shown to in£uence the prevalence and severity of UI Mommsen and Foldspang, 1994;Meyer et al, 1998].…”

Section: Discussionmentioning

confidence: 99%

Factors influencing self‐perceived disease severity in women with stress urinary incontinence combined with or without urge incontinence

Hong

et al. 2005

Neurourology and Urodynamics

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Factors influencing self‐perceived disease severity in women with stress urinary incontinence combined with or without urge incontinence

Hong

et al. 2005

Neurourology and Urodynamics

View full text Add to dashboard Cite

show abstract

“…7 OAB with UUI ('wet OAB') appears to affect QoL more than dry OAB. 14,[19][20][21] Results of the European survey published by Irwin et al 14 showed that participants with wet OAB were significantly more likely than those with dry OAB to express worry about having accidents and concern about participating in activities away from home. Accordingly, the results of the NOBLE program showed that OAB patients presented higher symptom bother scores than controls, with wet OAB patients reporting a higher impact of symptoms on physical function, role limitation, vitality, general health perception, bodily pain, and social function.…”

Section: Socioeconomic Burden Quality Of Life and Social Impactmentioning

confidence: 99%

Social, economic, and health utility considerations in the treatment of overactive bladder

Sacco

Tienforti²,

D’Addessi³

et al. 2010

RRU

View full text Add to dashboard Cite

Overactive bladder (OAB) is a highly prevalent urinary syndrome with a profound impact on quality of life (QoL) of affected patients and their family because of its adverse effects on social, sexual, interpersonal, and professional function. Cost-of-illness analyses showed the huge economic burden related to OAB for patients, public healthcare systems, and society, secondary to both direct and indirect costs; however, intangible costs related to QoL impact are usually omitted from these analyses. Recently many novel treatment modalities have been introduced and the need to apply the modern methodology of health technology assessment to these treatment strategies was immediately clear in order to evaluate objectively their value in term of both improvement in length/quality of life and costs. Health utilities are instruments that allow a measurement of QoL and its integration in the economic evaluation using the quality-adjusted life-years model and cost-utility analysis. The development of suitable instruments for quantifying utility in the specific group of OAB patients is vitally important to extend the application of cost-utility analysis in OAB and to guide healthcare resources allocation for this disorder. Studies are required to define the cost-effectiveness of available pharmacological and nonpharmacological therapy options for this disorder.

show abstract

“…The symptomatic burden of OAB is significant, with symptoms disrupting daily activities, sleep, mental health, and personal relationships 4,5 . Furthermore, OAB symptoms have a negative impact on health-related quality-of-life (HRQoL) 4,6,7 , and there is evidence that comorbidities such as depression, fractures, skin infections, and urinary tract infections may be associated directly with OAB 8 . In the US, the cost of OAB was estimated to be $65.9 billion in 2010, with $49.1 billion of direct medical costs; this was projected to increase to $76.2 billion and $82.6 billion in 2015 and 2020, respectively 9 .…”

Section: Introductionmentioning

confidence: 99%

Economic evaluation of pharmacological treatments for overactive bladder from the perspective of the UK National Health Service

Nazir

Posnett

Walker

et al. 2014

Journal of Medical Economics

View full text Add to dashboard Cite

Objective: To evaluate the costs and outcomes associated with different sequences of oral anti-muscarinic agents and the selective 3 -adrenoceptor agonist, mirabegron, for the treatment of overactive bladder (OAB). Methods:A Markov model with monthly cycle length and time horizon up to 3 years was designed to compare two different sequences of up to three lines of oral therapy for OAB. Patients who discontinued one oral medication could switch to another oral medication or could discontinue treatment. Patients whose symptoms were not controlled were considered for botulinum toxin or sacral nerve stimulation. Outcomes were measured by (a) number of patients with controlled symptoms (no incontinence episodes and58 micturitions per 24 h); (b) patients with no incontinence episodes per 24 hours; and (c) patients with 58 micturitions per 24 h. Results:Including a third-line oral medication before considering other treatment options improved all patient outcomes, irrespective of the specific drugs used. A three-line sequence including two generic (oxybutynin first line and tolterodine extended-release second line) and one branded drug (solifenacin 5 mg third line) resulted in inferior patient outcomes at costs similar to a sequence of branded drugs (mirabegron first line, solifenacin 5 mg second line, solifenacin 10 mg third line

show abstract

Relationship Between Patient Reports of Urinary Incontinence Symptoms and Quality of Life Measures

Cited by 82 publications

References 10 publications

Factors influencing self‐perceived disease severity in women with stress urinary incontinence combined with or without urge incontinence

Factors influencing self‐perceived disease severity in women with stress urinary incontinence combined with or without urge incontinence

Social, economic, and health utility considerations in the treatment of overactive bladder

Economic evaluation of pharmacological treatments for overactive bladder from the perspective of the UK National Health Service

Contact Info

Product

Resources

About